Intellia Therapeutics (NTLA) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Intellia Therapeutics

NasdaqGM•Healthcare•Biotechnology

$12.74+0.06(<0.01%)Market closed

Market Cap

$1.64B

P/S

27.5x

P/B

2.2x

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 9 (Cas9) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. It also has collaboration agreements with Regeneron Pharmaceuticals, Inc., SparingVision SAS, and Rewrite Therapeutics Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

How this company scores

AverageMetricSide Score: 49/100

Strongest: Growth (18/25); weakest: Cash & Earnings Quality (8/25).

Profitability8/25

Growth18/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality8/25

Strengths

Interest easily coveredProfit converts from growthConsistent growthNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 27.5x5y range 15.5x – 378.4x

Currently below its 20-quarter median.

P/B · 2.2x5y range 0.9x – 9.2x

Currently near its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $1.64B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $59.51M
Q. Revenue: $7.66M
TTM EBITDA: $-414.40M
TTM Op. Income: $-423.48M
Q. Op. Income: $-112.76M
TTM Net Income: $-399.98M
Q. Net Income: $-106.63M
EPS: $-0.8
Shares Out.: $133.48M

$59.51M in TTM revenue grew 12.6% YoY, reaching $7.66M last quarter. TTM EBITDA of $-414.40M and TTM operating income of $-423.48M show growth is flowing through to the bottom line. However, net income is negative at $399.98M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has fallen for 2 consecutive quarters — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: -1445.1%
Op. Margin: -1472.3%
Net Margin: -1392.3%

Op. margin of -1472.3% is down 700.1% YoY — costs are rising relative to revenue. Net margin at -1392.3% Across the last 8 quarters, operating margin has fallen for 2 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 27.5x
P/B Ratio: 2.2x

P/S of 27.5x and P/B of 2.2x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $857.16M
Cash: $106.13M
Long-Term Debt: N/A
Book Value: $727.71M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-83.11M
TTM Free Cash Flow: $-348.69M
FCF Margin: -586.0%
FCF / Net Income: 0.9

TTM FCF of $-348.69M on $-83.11M in operating cash flow. The FCF / Net Income ratio of 0.9x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 4 consecutive quarters — an improving trend.